Aspira Pathlab & Diagnostics

Aspira Pathlab & Diagnostics Non-Current Assets

The Non-Current Assets of Aspira Pathlab & Diagnostics (540788.BO) as of Nov 2, 2026 is 67.33 M INR. In the previous year, Non-Current Assets was 59.99 M INR — a change of 12.22% (higher).

Non-Current Assets

67.33 MINR

YoY

12.22%

Last updated:

Non-Current Assets of Aspira Pathlab & Diagnostics is 2025 67.33 M INR. Non-Current Assets of Aspira Pathlab & Diagnostics was 2024 59.99 M INR. It decreases by 12.22% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aspira Pathlab & Diagnostics Stock analysis

What does Aspira Pathlab & Diagnostics do? Aspira Pathlab & Diagnostics Ltd generates revenue through pathology investigation services, radiology investigation services, and health packages at its diagnostic centers in Mumbai. The company offers specialized tests such as the Shanti Screening Test, COVID-19 Antibody Test, and COVID-19 RT-PCR Test, which are part of its diagnostic services portfolio. Customers include individuals seeking health screenings, patients requiring medical diagnostics, and healthcare providers who refer clients to its facilities. The firm's services are segmented into pathology, radiology, and health packages, with a focus on high-demand tests like COVID-19 detection profiles. The company's revenue streams are derived from conducting various pathological investigations across branches like biochemistry, hematology, and microbiology. Its health packages and pathology tests, including the COVID-19 Detection Profile 1 and 2, cater to both individual and institutional clients. The firm operates within the healthcare sector, providing diagnostic solutions for patients and medical professionals in Mumbai, with a particular emphasis on pandemic-related testing services during the global health crisis. Aspira Pathlab & Diagnostics Ltd monetizes its diagnostic capabilities through a mix of routine pathology services and specialized health packages. The Shanti Screening Test and other COVID-19-related tests form a significant portion of its revenue, especially during periods of high demand for pandemic testing. The company serves a broad customer base, including individuals, clinics, and hospitals that rely on its diagnostic expertise for accurate medical assessments. Aspira Pathlab & Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aspira Pathlab & Diagnostics stock

Non-Current Assets of Aspira Pathlab & Diagnostics is 67.33 M INR in 2025.

Non-Current Assets of Aspira Pathlab & Diagnostics changed from 59.99 M INR to 67.33 M INR, representing a 12.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Non-Current Assets Aspira Pathlab & Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Non-current assets are long-term resources not expected to be converted to cash within one year, including property, equipment, and long-term investments.

Non-Current Assets's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Non-Current Assets's Aspira Pathlab & Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Aspira Pathlab & Diagnostics

All Key Metrics — Aspira Pathlab & Diagnostics